We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Newly Discovered Protein Blocks Tumor Growth

By Biotechdaily staff writers
Posted on 18 Nov 2004
Investigators have discovered that a form of vascular endothelial growth factor (VEGF) present in normal blood and tissue can prevent tumor growth. More...


A team of scientists at Bristol University (UK) has called the new type of factor VEGF165b, which was found to inhibit the growth of new blood vessels required for tumors to grow greater than 1 mm. The scientists have also found that VEGF is usually found in many areas of the body, including the prostate, but not in prostate tumors, and have figured out how this form of VEGF works with blood vessels.

Knowing how VEGF165b functions, and its effects on tumors, means that it could be possible to prevent the growth of tumors by starving the tumor using the body's own antitumor agent. The benefits of using this protein over conventional compounds to treat cancer is that VEGF156b is a natural protein made by the body under normal conditions. Many new cancer treatments are based on depriving the tumor of nutrients by attacking the blood supply of the tumor rather than the cancer cells. Blocking VEGF using antibodies has recently been demonstrated to be effective in large-scale trials with colorectal cancer patients in the United States.

One problem with this therapy will be that new blood vessel growth is needed for many body processes. However, it is believed that adults can live normally without blood vessel growth for extended time periods.

"Now that we have found out that this protein works in living tissues, we need to find the best way of using it in cancer, with tumor models. We also need to try it in models of other diseases where blood vessel growth is necessary, such as diabetes, age-related macular degeneration, and arthritis,” said Dr. David Bates, from Bristol University.

Dr. Steve Harper, another researcher from Bristol University, stated, "After two years of hard work, it is a big step to show that this protein works in real cancers. We hope to be able to take this forward in the next few years to work out how to treat patients with cancer, eye disease, and other conditions where this protein is important.”




Related Links:
Bristol University

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.